Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNM001 injection for prevention of RSV lower respiratory tract infection in infants
CTR20232792Phase 3Completed
- Sponsor
- Trinomab Pharmaceutical
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of TNM001 in respiratory syncytial virus disease (RSV), sponsored by Trinomab Pharmaceutical. Started Sep 2023; status: completed.
02
Drugs
TNM001
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20232792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232792.